A Multicenter, Randomized, Double-Blind, Double-Dummy Trial of Azithromycin SR Compared With Levofloxacin for the Treatment of Mild to Moderate Pneumonia in Adult Patients
NCT ID: NCT00643734
Last Updated: 2008-03-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
468 participants
INTERVENTIONAL
2003-04-30
2004-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
azithromycin sustained release
azithromycin SR 2.0 g by mouth in the form of a slurry for 1 dose
placebo
placebo
2
levofloxacin
500 mg (two 250 mg capsules) by mouth once daily for 7 days
placebo
placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
azithromycin sustained release
azithromycin SR 2.0 g by mouth in the form of a slurry for 1 dose
placebo
placebo
levofloxacin
500 mg (two 250 mg capsules) by mouth once daily for 7 days
placebo
placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Pfizer, Inc.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Mesa, Arizona, United States
Pfizer Investigational Site
Phoenix, Arizona, United States
Pfizer Investigational Site
San Luis Obispo, California, United States
Pfizer Investigational Site
San Mateo, California, United States
Pfizer Investigational Site
Highlands Ranch, Colorado, United States
Pfizer Investigational Site
Newark, Delaware, United States
Pfizer Investigational Site
Kissimmee, Florida, United States
Pfizer Investigational Site
Merrit Island, Florida, United States
Pfizer Investigational Site
Evansville, Indiana, United States
Pfizer Investigational Site
Evansville, Indiana, United States
Pfizer Investigational Site
Indianapolis, Indiana, United States
Pfizer Investigational Site
Dubuque, Iowa, United States
Pfizer Investigational Site
Pratt, Kansas, United States
Pfizer Investigational Site
Madisonville, Kentucky, United States
Pfizer Investigational Site
Cumberland, Maryland, United States
Pfizer Investigational Site
Kalamazoo, Michigan, United States
Pfizer Investigational Site
Olive Branch, Mississippi, United States
Pfizer Investigational Site
Elkhorn, Nebraska, United States
Pfizer Investigational Site
Omaha, Nebraska, United States
Pfizer Investigational Site
Rio Rancho, New Mexico, United States
Pfizer Investigational Site
Charlotte, North Carolina, United States
Pfizer Investigational Site
Charlotte, North Carolina, United States
Pfizer Investigational Site
Charlotte, North Carolina, United States
Pfizer Investigational Site
Hickory, North Carolina, United States
Pfizer Investigational Site
Yukon, Oklahoma, United States
Pfizer Investigational Site
Downingtown, Pennsylvania, United States
Pfizer Investigational Site
King of Prussia, Pennsylvania, United States
Pfizer Investigational Site
Morrisville, Pennsylvania, United States
Pfizer Investigational Site
Greer, South Carolina, United States
Pfizer Investigational Site
Dyersburg, Tennessee, United States
Pfizer Investigational Site
Lake Jackson, Texas, United States
Pfizer Investigational Site
Salt Lake City, Utah, United States
Pfizer Investigational Site
Salt Lake City, Utah, United States
Pfizer Investigational Site
Walla Walla, Washington, United States
Pfizer Investigational Site
Menomonee Falls, Wisconsin, United States
Pfizer Investigational Site
Langley, British Columbia, Canada
Pfizer Investigational Site
Hawkesbury, Ontario, Canada
Pfizer Investigational Site
Kitchener, Ontario, Canada
Pfizer Investigational Site
Toronto, Ontario, Canada
Pfizer Investigational Site
Montreal, Quebec, Canada
Pfizer Investigational Site
Pointe-Claire, Quebec, Canada
Pfizer Investigational Site
Ste-foy, Quebec, Canada
Pfizer Investigational Site
Victoriaville, Quebec, Canada
Pfizer Investigational Site
North Battleford, Saskatchewan, Canada
Pfizer Investigational Site
Saskatoon, Saskatchewan, Canada
Pfizer Investigational Site
Providencia, Santiago Metropolitan, Chile
Pfizer Investigational Site
Bangalore, Karnataka, India
Pfizer Investigational Site
Bangalore, Karnataka, India
Pfizer Investigational Site
Indore, Madhya Pradesh, India
Pfizer Investigational Site
Mumbai, Maharashtra, India
Pfizer Investigational Site
Nagpur, Maharashtra, India
Pfizer Investigational Site
Chennai, Tamil Nadu, India
Pfizer Investigational Site
Vellore, Tamil Nadu, India
Pfizer Investigational Site
Alytus, , Lithuania
Pfizer Investigational Site
Kaunas, , Lithuania
Pfizer Investigational Site
Klaipėda, , Lithuania
Pfizer Investigational Site
Monterrey, Nuevo León, Mexico
Pfizer Investigational Site
San Isidro, Lima region, Peru
Pfizer Investigational Site
San Miguel, Lima region, Peru
Pfizer Investigational Site
Moscow, , Russia
Pfizer Investigational Site
Moscow, , Russia
Pfizer Investigational Site
Moscow, , Russia
Pfizer Investigational Site
Moscow, , Russia
Pfizer Investigational Site
Moscow, , Russia
Pfizer Investigational Site
Smolensk, , Russia
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A0661103
Identifier Type: -
Identifier Source: org_study_id